When GlaxoSmithKline announced yesterday that it was pulling out of research into selected neuroscience areas like depression and pain, it signalled a new round of job cuts at the company. Last year, GSK reduced its headcount by around 6,000 people.
Although CEO Andrew Witty wouldn’t be drawn on just how many positions would have to go this time, the figure...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?